Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
Bone Marrow Transplantation|March 6, 2019
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantationStefan O Ciurea, Monzr M Al Malki, Piyanuch Kongtim, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 24, 2005
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell helpMichele A Kutzler, Tara M Robinson, Michael A Chattergoon, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Blood|July 2, 2015
Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemiaStefan O Ciurea, Mei-Jie Zhang, Andrea A Bacigalupo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2015
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older AdultsYvette L Kasamon, Javier Bolaños-Meade, Gabrielle T Prince, et al.
Haematologica|November 16, 2016
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamideShannon R McCurdy, Yvette L Kasamon, Christopher G Kanakry, et al.
Haematologica|May 8, 2025
Improved outcomes of acute lymphoblastic leukemia after allogeneic blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in the era of more effective pre-transplant therapyJonathan A Webster, Madison Reed, Hua-Ling Tsai, et al.
Blood Advances|October 5, 2019
Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancyScott R Solomon, Andrew St Martin, Nirav N Shah, et al.
Pageof 15